Trials / Completed
CompletedNCT00427687
Study Evaluating AGG-523 in Subjects With Osteoarthritis
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel-Group Study of the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of AGG-523 Administered Orally to Subjects With Mild to Moderate Osteoarthritis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGG-523 |
Timeline
- Start date
- 2007-02-01
- Completion
- 2007-06-01
- First posted
- 2007-01-29
- Last updated
- 2008-08-05
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00427687. Inclusion in this directory is not an endorsement.